Skip to Main Content (Press Enter)

Logo UNINSUBRIA
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze

UNI-FIND
Logo UNINSUBRIA

|

UNI-FIND

uninsubria.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze
  1. Pubblicazioni

Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely Ill medical patients: An APEX trial substudy

Articolo
Data di Pubblicazione:
2017
Abstract:
Background-Extended-duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and safety events, one approach to assess net clinical outcomes is to include only those events that are either fatal or cause irreversible harm. Methods and Results-This was a post hoc analysis of the APEX trial-a multicenter, double-blind, randomized controlled trial comparing extended-duration betrixaban versus standard-of-care enoxaparin. A composite of all fatal or irreversible safety (fatal bleeding or intracranial hemorrhage) and efficacy events (cardiopulmonary death, myocardial infarction, pulmonary embolism, and ischemic stroke) was evaluated in a time-to-first event analysis. In patients with positive D-dimer results, betrixaban reduced fatal or irreversible events at 35 to 42 days (4.80% versus 3.54%; hazard ratio, 0.73; absolute risk reduction, 1.26%; number needed to treat, 79 [P=0.033]) and at study end at 77 days (6.27% versus 4.36%; hazard ratio, 0.70; absolute risk reduction, 1.91%; number needed to treat, 52 [P=0.005]) versus enoxaparin. In all patients, betrixaban reduced fatal or irreversible events at 35 to 42 days (4.08% versus 2.90%; hazard ratio, 0.71; absolute risk reduction, 1.18%; number needed to treat, 86 [P=0.006]) and 77 days (5.17% versus 3.64%; hazard ratio, 0.70; absolute risk reduction, 1.53%; number needed to treat, 65 [P=0.002]). Conclusions-Among hospitalized medically ill patients, extended-duration betrixaban demonstrated an ≈ 30% reduction in fatal or irreversible ischemic or bleeding events compared with standard-duration enoxaparin. A total of 65 patients would require treatment with betrixaban to prevent 1 fatal or irreversible event versus enoxaparin.
Tipologia CRIS:
Articolo su Rivista
Keywords:
Death; Intracranial hemorrhage; Ischemic stroke; Myocardial infarction; Pulmonary embolism; Venous thromboembolism
Elenco autori:
Gibson, C. M.; Korjian, S.; Chi, G.; Daaboul, Y.; Jain, P.; Arbetter, D.; Goldhaber, S. Z.; Hull, R.; Hernandez, A. F.; Lopes, R. D.; Gold, A.; Cohen, A. T.; Harrington, R. A.; Bello, F.; Ferrari, A. E.; Jure, H.; Macin, S.; Oliva, M.; Parody, M.; Poy, C.; Baker, R.; Colquhoun, D.; Coughlin, P.; Finfer, S.; Hammerschlag, G.; Rubinfeld, A.; Huber, K.; Konig, J.; Mathies, R.; Pilger, E.; Schoenerr, H.; Adzerikho, I.; Koryk, V.; Mikhailova, E.; Mitkovskaya, N.; Pimanov, S.; Polonetsy, L.; Soroka, N.; Blockmans, D.; Delforge, M.; Dive, A.; Lienart, F.; Motte, S.; Annichino Bizzacchi, J.; Fiss, E.; Freire, A.; Manenti, E.; Ramacciotti, E.; Raymuno, S.; Rocha, A.; Saraiva, J. F.; Dimov, B.; Grigorov, M.; Kalpachki, R.; Kamenova, Z.; Kostadinova, M.; Milanova, M.; Mincheva, V.; Pencheva, G.; Raev, D.; Runev, N.; Stoeva, N.; Stoyanov, M.; Syulemzova, S.; Todorov, G.; Tokmakova, M.; Dhar, A.; Douketis, J.; Kahn, S.; Le Gal, G.; Pearce, M.; Provencher, S.; Verreault, S.; Arias Alarcon, M.; Olivares Canon, C.; Opazo Lazcano, M.; Potthoff Cardenas, S.; Butkovic-Soldo, S.; Car, S.; Ciglenecki, N.; Francetic, I.; Jakopovic, M.; Kalinic-Grgorinic, H.; Knezevic, A.; Malojcic, B.; Marusic, S.; Sikic Vagic, J.; Skerk, V.; Cermak, O.; Cervinka, P.; Chlumsky, J.; Chochola, J.; Cizek, V.; Dunaj, M.; Dusek, J.; Francek, L.; Havelka, J.; Herold, M.; Holaj, R.; Horny, I.; Hubac, J.; Jajtner, P.; Kolman, P.; Lang, P.; Mayer, O.; Mikulova, J.; Podpera, I.; Reiterer, P.; Spacek, R.; Vejvoda, J.; Vyhnanek, M.; Christensen, H.; Lassen, M.; Storgaard, M.; Tuxen, C.; Urhammer, S.; Lember, M.; Marandi, T.; Uuetoa, T.; Airaksinen, J.; Honkaniemi, J.; Kaaja, R.; Lassila, R.; Saarinen, J.; Tatlisumak, T.; Vikman, S.; Agraou, B.; Aquilanti, S.; Belhassane, A.; Brisot, D.; De Geeter, G.; Debourdeau, P.; Decoulx, E.; El Kouri, D.; Falvo, N.; Grange, C.; Lacroix, P.; Messas, E.; Mismetti, P.; Montaclair, K.; Mottier, D.; Paleiron, N.; Payot, L.; Pernod, G.; Pottier, P.; Proust, A.; Quere, I.; Roy, P. -M.; Schmidt, J.; Simoneau, G.; Datikashvili-David, I.; Khabeishvili, G.; Khintibidze, I.; Kobulia, B.; Megreladze, I.; Pagava, Z.; Paposhvili, K.; Shaburishvili, T.; Amann, B.; Berrouschot, J.; Beyer-Westendorf, J.; Blessing, E.; Bott, M.; Dengler, T.; Diehm, C.; Dziewas, R.; Genth-Zotz, S.; Hamann, F.; Horacek, T.; Klimpe, S.; Kroning, R.; Lapp, H.; Lawall, H.; Licka, M.; Rizos, T.; Schellong, S.; Schmidt-Lucke, J.; Singer, C.; Tiefenbacher, C.; Veltkamp, R.; Weimar, C.; Zeymer, U.; Alkonyi, B.; Falukozy, J.; Futo, L.; Katona, A.; Kirschner, R.; Kristof, P.; Lakatos, F.; Laszlo, Z.; Lupkovics, G.; Merkely, B.; Nagy Andras, C.; Nemeth, L.; Papp, A.; Soltesz, P.; Sudar, Z.; Szabo, G.; Szegedi, N.; Timar, G.; Valco, J.; Vertes, A.; Efrati, S.; Elias, M.; Gafter, A.; Hayek, T.; Hussein, O.; Lishner, M.; Lugassy, G.; Zeltser, D.; Ageno, W.; Cerveri, I.; D'Angelo, A.; De Pellegrin, A.; Imberti, D.; Landolfi, R.; Lembo, G.; Lodigiani, C.; Luisetti, M.; Moia, M.; Molteni, M.; Mumoli, N.; Novo, S.; Orlandini, F.; Parisi, R.; Pizzini, A.; Pomero, F.; Salvi, A.; Schenone, A.; Visona, A.; Krievins, D.; Martinova, V.; Pontaga, N.; Rozitis, V.; Stukena, I.; Alekniene, B.; Bagdonas, A.; Basijokiene, V.; Butkiene, Z.; Griskeviciene, V.; Naudziunas, A.; Norvaisiene, R.; Norviliene, R.; Petrauskiene, R.; Poskiene, R.; Susinskiene, D.; Valavicius, A.; Castillo Leon, R.; Cotrina Pereyra, R.; Farjardo Karlo, L.; Horna, M.; Lema Osores, J.; Salas, M.; Toche Yanez, L.; Fryze, W.; Gaciong, Z.; Gniot, J.; Gorecka, D.; Gruenpeter, P.; Grzelakowski, P.; Jastrzebski, D.; Kucharski, L.; Mirek-Bryniarska, E.; Pulkowski, G.; Sobkowicz, B.; Sulik, P.; Tomkowski, W.; Walasek, L.; Waldemar, K.; Wrzesinski, K.; Balogh, Z. E.; Bojinca, M.; Marin, I.; Mot, S.; Musetescu, R.; Podoleanu, C.; Popescu, M.; Stamate, S.; Stanciulescu, G.; Vida-Simiti, L.; Abashev, A.; Andreev, D.; Apartsin, K.; Arkhipov, M.; Averkov, O.; Barbarash, O.; Belskaya, G.; Bogdanov, E.; Boldueva, S.; Chefranova, Z.; Dovgalevskiy, Y.
Link alla scheda completa:
https://irinsubria.uninsubria.it/handle/11383/2098264
Pubblicato in:
JOURNAL OF THE AMERICAN HEART ASSOCIATION. CARDIOVASCULAR AND CEREBROVASCULAR DISEASE
Journal
  • Accessibilità
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.2.0